Vandetanib Had Antitumor Activity In RET-rearranged NSC Lung Cancer

MedicalResearch.com Interview with:
Dr Kiyotaka Yoh

Department of Thoracic Oncology
National Cancer Center Hospital East
Kashiwa, Japan

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: LURET is multicenter, single-arm, phase II study to evaluate the efficacy and safety of vandetanib as RET inhibitor in patients with advanced RET-rearranged non-small-cell lung cancer (NSCLC). In 2012, RET rearrangements were identified as rare oncogenic alterations for NSCLC.

Among 17 eligible patients included in primary analysis, the objective response rate was 53% (95% CI 28–77), which met the primary endpoint. At the data cutoff, median progression-free survival was 4.7 months (95% CI 2.8–8.5). Overall, vandetanib was tolerated, with an adverse event profile similar to those seen in previous large population studies of vandetanib in patients with unselected NSCLC.

MedicalResearch.com: What should readers take away from your report?

Response: Our study showed that vandetanib exhibited clinical antitumor activity in patients with advanced RET-rearranged NSCLC. Our results define RET rearrangement as a new molecular subgroup of NSCLC suitable for targeted therapy.

MedicalResearch.com: What recommendations do you have for future research as a result of this study?

Response: Interestingly, our results showed differences in vandetanib efficacy according to the type of RET fusion. Patients with CCDC6-RET had a much higher response and a longer survival after vandetanib treatment than did those with KIF5B-RET. Further investigation is needed to elucidate whether sensitivity to RET inhibitor differed among different RET fusions forms.

MedicalResearch.com: Is there anything else you would like to add?

Response: The RET inhibitor vandetanib is effective in RET-rearranged NSCLC patients. Although further large confirmatory studies are warranted, our results have important implications for RET-directed therapy in patients with NSCLC.

Study drug was supported by AstraZeneca and Sanofi and its subsidiary Genzyme.

MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.

Citation:

Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
Yoh, Kiyotaka et al.
The Lancet Respiratory Medicine , Volume 5 , Issue 1 , 42 – 50
DOI: http://dx.doi.org/10.1016/S2213-2600(16)30322-8
November 2016

Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.

More Medical Research Interviews on MedicalResearch.com

[wysija_form id=”5″]

No Comments

Sorry, the comment form is closed at this time.